Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Bristol Myers Squibb presented two-year Sotyktu data in adults with psoriatic arthritis showing durable efficacy and a consistent safety profile. The update supports the long-term clinical positioning of Sotyktu, though the headline provides no detailed efficacy metrics, safety-event rates, or commercial guidance.